There are headlines about HIV treatment that feel like science fiction—until you realize they’re very much happening in real labs, with real patients, and very real implications. This is one of them.
Researchers at Imperial College London have been testing a treatment built from two broadly neutralising antibodies (bNAbs)—immune system proteins designed to recognize and block HIV in ways the virus finds harder to escape. Early results suggest something that would have sounded almost unthinkable not too long ago: some people may be able to pause daily HIV medication for extended periods, in some cases up to two years.
That doesn’t mean HIV is suddenly “gone” or cured. But it does mean the way we manage it might be shifting in ways that matter deeply for quality of life.
A trial built around a different kind of control
The study, published in The Lancet HIV, involved 68 participants in the UK and Denmark. All of them were already living with HIV that was well controlled using antiretroviral therapy (ART), the standard long-term treatment that keeps the virus suppressed. Advertisement
ART is extremely effective. It keeps HIV at undetectable levels, meaning it cannot be transmitted sexually and allows people to live long, healthy lives. But it comes with one unchanging requirement: consistency. Daily medication, lifelong.
In this trial, participants received either the antibody treatment or a placebo. After that, they stopped taking their usual ART under close medical supervision—essentially testing whether the immune-based therapy could hold the line on its own.
What happened when treatment stopped
The results were cautiously striking.
- 75% of participants who received the antibody treatment maintained viral control 20 weeks after stopping ART
- Around half remained off medication for one year
- About a quarter continued viral suppression for up to two years
That last figure is the one that inevitably draws attention. A subset of participants maintained control of the virus far longer than expected without daily medication, suggesting that in some cases, immune-based therapies might help extend the time between treatments.
Why antibodies matter here
The treatment used two antibodies—3BNC117-LS and 10-1074-LS—that target different parts of HIV. The idea is not to eliminate the virus entirely (HIV is notoriously good at hiding in dormant reservoirs), but to corner it more effectively when it tries to reactivate.
Unlike ART, which suppresses replication continuously, these antibodies act more like highly specific blockers, giving the immune system a chance to keep HIV in check without constant drug pressure. Advertisement
It’s not a replacement for ART today. But it is a different strategy: less about daily suppression, more about long-acting immune control.
“Closer to a cure” is doing a lot of work here
Researchers are careful with language, and for good reason. HIV remains incurable. Even when viral levels are undetectable, the virus can persist in hidden reservoirs and rebound if treatment fully stops.
Still, the optimism in the research team is clear.
“These results open new possibilities for HIV treatment and bring us closer to our goal of finding a cure” – Prof Sarah Fidler of Imperial College London
And, in a more technical framing of the findings:
“These results open new possibilities for HIV treatment and bring us closer to our goal of finding a cure.”
It’s the kind of statement that signals progress without pretending the job is finished.
Where this fits in the bigger picture
What makes this study notable is not that it eliminates HIV—it doesn’t—but that it pushes at one of the longest-standing assumptions in HIV care: that suppression requires daily medication, without exception. Advertisement
For people living with HIV, the possibility of extended treatment breaks, even if only for some patients in the future, changes the emotional and practical math of the condition. Fewer daily reminders. Less medication fatigue. More flexibility in how treatment is experienced, not just how it works biologically.
And that sits alongside another quieter trend: new UK data shows HIV diagnoses continuing to fall, from 3,169 in 2023 to 3,043 in 2024, as public health efforts push toward ending new transmissions by 2030.
Not a finish line, but a shift in direction
It’s easy to read a result like this and jump straight to “breakthrough” or “game changer.” The reality is more measured, but still meaningful.
This is early evidence that immune-based therapies could one day complement—or in some cases reduce reliance on—daily HIV medication. Not replace care, not erase complexity, but potentially reshape it. Advertisement
For now, ART remains the gold standard. But studies like this are starting to map out what the next generation of HIV treatment might look like: longer-lasting, less rigid, and a little closer to what patients have been waiting for since the earliest days of the epidemic—not just control, but breathing room.
